UPDATE : Wednesday, June 19, 2019
상단여백
294 shareholders file suit against Kolon TissueGene for damage compensation
Kolon TissueGene said in a public filing on Thursday that its 294 minority ...
by Jeong Sae-im  |  2019-06-14 10:51
라인
Celltrion unveils P3 trial results for rheumatoid biosimilar in Europe
Celltrion has presented the phase 3 clinical trial result for Remsima SC, t...
by Lee Han-soo  |  2019-06-13 16:10
라인
Kolon TissueGene CEO resigns
Kolon TissueGene, a subsidiary of Kolon Life Science, said Co-CEO Lee Woo-s...
by Jeong Sae-im  |  2019-06-07 15:35
라인
[ASCO 2019] ‘Ontruzant demonstrates equal quality to original drug’
CHICAGO, Ill. -- Samsung Bioepis has proved its quality control ability, as...
by Lee Han-soo, KBR correspondent  |  2019-06-04 14:17
라인
Kolon’s minority shareholders demand over ₩25 billion in damage
Minority shareholders of Kolon Life Science and its subsidiary Kolon Tissue...
by Jeong Sae-im  |  2019-06-03 14:53
라인
Invossa inventor sold Kolon shares at highest value
Former Kolon TissueGene CEO Lee Kwan-hee, the inventor of now-suspended gen...
by Jeong Sae-im  |  2019-06-03 14:52
라인
Until when will Kolon keep lying about Invossa?
Kolon Life Science’s “explanations” about the mislabeling of the cell ingre...
by Jeong Sae-im  |  2019-05-31 14:59
라인
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug
Samsung BioLogics said it has signed a deal with U.S. biotech firm CytoDyn ...
by Jeong Sae-im  |  2019-05-31 14:59
라인
Announcement of Invossa license revocation was ‘procedural breach’: Kolon
The government’s recent announcement that it would nullify the license of I...
by Jeong Sae-im  |  2019-05-30 13:28
라인
‘MDM2 gene’ may be associated with hyperprogression after immunotherapy
Oncology researchers around the world are paying keen attention to MDM2 (mo...
by Kim Yun-mi  |  2019-05-29 12:35
라인
Invossa poses almost no safety threat: regulator
The Ministry of Food and Drug Safety said there was no significant concern ...
by Lee Hye-seon  |  2019-05-28 16:02
라인
Brazil OKs Samsung Bioepis’ trastuzumab biosimilar
Brazil’s Agencia Nacional de Vigilancia Sanitaria has granted marketing aut...
by Lee Han-soo  |  2019-05-27 15:52
라인
‘Shareholders can surely win lawsuit against Kolon’
Law firm Hankyul is pursuing a lawsuit against Kolon Life Science and Kolon...
by Jeong Sae-im  |  2019-05-24 19:34
라인
‘Kolon’s extra data insufficient to explain Invossa mislabeling’
The Ministry of Food and Drug Safety said additional material submitted by ...
by Lee Hye-seon  |  2019-05-23 14:51
라인
Prosecutors seek arrest warrant of Samsung BioLogics CEO
The Seoul Central District Prosecutors Office is seeking an arrest warrant ...
by Lee Han-soo  |  2019-05-23 11:19
라인
[News Focus] Kolon, regulator rapped for not doing enough to quell concerns of patients
More than 50 days have passed since the Ministry of Food and Drug Safety (M...
by Jeong Sae-im  |  2019-05-22 11:59
라인
Legislator, activists call for revoking Invossa license, conducting probes
A lawmaker and civic groups urged the government to nullify the license of ...
by Jeong Sae-im  |  2019-05-21 16:03
라인
Kolon to follow 3,700 Invossa-treated patients for 15 years
Kolon Life Science said it would conduct a long-term follow-up study on ove...
by Jeong Sae-im  |  2019-05-17 15:38
라인
Will Celltrion CEO’s bet on ‘bio valley’ pay off?
“It’s been 19 years since I started this business. The first decade was a t...
by Jeong Sae-im  |  2019-05-17 13:21
라인
CHA Biotech’s operating income plunges 92% in Q1
CHA Biotech said in a public filing on Wednesday that it recorded 124.4 bil...
by Jeong Sae-im  |  2019-05-16 13:41
여백
여백
여백
Back to Top